Creative Medical received a USPTO Notice of Allowance for a U.S. patent application covering exosome-based immunotherapy for Type 1 diabetes.
Application 17/931,868 targets exosomes from stem-cell-programmed myeloid cells to induce immune tolerance and protect pancreatic beta cells.
Allowed claims include use alone or with other tolerance-promoting therapies; intended to broaden protection around the MyeloCelz platform.
The company cited prior diabetes-related patents issued as U.S. Patent Nos. 12,931,925 and 12,385,011, with protection into 2042 and 2043.
The portfolio includes CELZ-201 in the FDA-cleared CREATE-1 trial, CELZ-101 with FDA Orphan Drug Designation, supported by about 60 patents and applications.
CELZ•
